Published in Transl Res on February 08, 2011
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics (2012) 1.63
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res (2012) 1.22
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J (2011) 1.09
Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05
Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines. Pharmacogenomics (2014) 1.00
Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One (2011) 0.99
Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes? Pharmacogenomics (2013) 0.95
Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics (2012) 0.94
Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer (2012) 0.89
Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med (2012) 0.89
Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility. Mol Cancer Ther (2012) 0.88
Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res (2012) 0.87
Reprogramming LCLs to iPSCs Results in Recovery of Donor-Specific Gene Expression Signature. PLoS Genet (2015) 0.86
SCAN: a systems biology approach to pharmacogenomic discovery. Methods Mol Biol (2013) 0.85
Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet (2013) 0.84
Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther (2014) 0.84
Genetically InFormed therapies--a "GIFT" for children with cancer. Clin Cancer Res (2012) 0.83
Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet (2014) 0.83
An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet (2011) 0.83
In vitro human cell line models to predict clinical response to anticancer drugs. Pharmacogenomics (2015) 0.79
EPS8 inhibition increases cisplatin sensitivity in lung cancer cells. PLoS One (2013) 0.78
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourin Cancer (2016) 0.76
Utility of Lymphoblastoid Cell Lines for Induced Pluripotent Stem Cell Generation. Stem Cells Int (2016) 0.75
Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci (2017) 0.75
Integrative "omic" analysis for tamoxifen sensitivity through cell based models. PLoS One (2014) 0.75
Exceptional Durable Response to Everolimus in a Patient with Biphenotypic Breast Cancer Harboring an STK11 Variant. Cold Spring Harb Mol Case Stud (2017) 0.75
A haplotype map of the human genome. Nature (2005) 105.70
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
SCAN: SNP and copy number annotation. Bioinformatics (2009) 5.96
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst (2007) 3.85
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A (2010) 2.43
Genome-wide association studies in pharmacogenomics. Nat Rev Genet (2010) 2.14
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol (2010) 1.90
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol (2009) 1.74
SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol (2009) 1.70
Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther (2008) 1.67
Concurrent chemoradiation with carboplatin-5-fluorouracil versus cisplatin in locally advanced oropharyngeal cancers: is more always better? Int J Radiat Oncol Biol Phys (2009) 1.51
The histidine triad protein Hint1 triggers apoptosis independent of its enzymatic activity. J Biol Chem (2006) 1.32
Site selectivity of platinum anticancer therapeutics. Nat Chem Biol (2007) 1.14
Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics (2005) 1.13
Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics (2009) 1.04
Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res (2010) 1.01
Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet Genomics (2010) 0.97
Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma. Cancer Lett (2008) 0.95
Is the histidine triad nucleotide-binding protein 1 (HINT1) gene a candidate for schizophrenia? Schizophr Res (2008) 0.93
Hypofractionated accelerated radiotherapy with concurrent carboplatin for locally advanced squamous cell carcinoma of the head and neck. Clin Oncol (R Coll Radiol) (2010) 0.93
The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim Biophys Acta (2002) 0.91
Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury: pharmacological and toxicological implications. Pharmacol Ther (2009) 0.90
Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin Cancer Res (2010) 0.87
Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer. Curr Opin Oncol (2010) 0.85
Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol (2010) 0.83
Head and neck squamous cell carcinoma: optimizing the therapeutic index. Expert Rev Anticancer Ther (2005) 0.83
Association of the histidine-triad nucleotide-binding protein-1 (HINT1) gene variants with nicotine dependence. Pharmacogenomics J (2010) 0.82
Finding the missing heritability of complex diseases. Nature (2009) 67.95
Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science (2009) 25.61
Influenza-associated hospitalizations in the United States. JAMA (2004) 18.23
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med (2009) 15.02
Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med (2005) 14.59
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol (2009) 12.13
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet (2010) 10.75
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep (2010) 10.59
The allelic architecture of human disease genes: common disease-common variant...or not? Hum Mol Genet (2002) 10.08
The global circulation of seasonal influenza A (H3N2) viruses. Science (2008) 10.05
ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med (2008) 9.13
Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science (2009) 8.61
A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science (2007) 8.38
Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA (2006) 8.06
Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol (2005) 7.88
Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med (2005) 6.83
Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A (2006) 6.35
A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A (2012) 6.27
Transmission of equine influenza virus to dogs. Science (2005) 6.11
SCAN: SNP and copy number annotation. Bioinformatics (2009) 5.96
Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. J Infect Dis (2002) 5.92
Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep (2009) 5.80
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet (2005) 5.70
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep (2007) 5.32
Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis (2007) 5.21
Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2006) 5.19
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2004) 5.00
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet (2011) 4.26
Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet (2005) 4.15
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 4.01
Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med (2013) 3.88
Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A (2007) 3.77
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol (2012) 3.62
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2005) 3.50
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc (2010) 3.44
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
Genetic architecture of transcript-level variation in humans. Am J Hum Genet (2008) 3.36
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2005) 3.28
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2002) 3.27
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. Virology (2011) 3.19
Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst (2003) 3.09
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol (2008) 3.02
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2003) 2.96
Identification of type 2 diabetes genes in Mexican Americans through genome-wide association studies. Diabetes (2007) 2.91
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol (2012) 2.76
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Serologic evidence of H1 swine Influenza virus infection in swine farm residents and employees. Emerg Infect Dis (2002) 2.75
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet (2011) 2.68
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine (2008) 2.56
Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol (2004) 2.51
Isolation and characterization of avian influenza viruses, including highly pathogenic H5N1, from poultry in live bird markets in Hanoi, Vietnam, in 2001. J Virol (2005) 2.51
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol (2009) 2.45
Genetic analysis of human H2N2 and early H3N2 influenza viruses, 1957-1972: evidence for genetic divergence and multiple reassortment events. Virology (2004) 2.44
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A (2010) 2.43
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol (2008) 2.40
Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog (2008) 2.38
Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment. J Virol (2009) 2.33
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol (2009) 2.32
A nondegenerate code of deleterious variants in Mendelian loci contributes to complex disease risk. Cell (2013) 2.28
Effect of receptor binding domain mutations on receptor binding and transmissibility of avian influenza H5N1 viruses. Virology (2011) 2.28
Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med (2008) 2.24
Pause on avian flu transmission research. Science (2012) 2.24
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol (2005) 2.18
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
Family clustering of avian influenza A (H5N1). Emerg Infect Dis (2005) 2.04